Changeflow GovPing Healthcare & Life Sciences Fusion Proteins With Specificity for Type II Co...
Routine Rule Added Final

Fusion Proteins With Specificity for Type II Collagen and VEGF-A for the Treatment of Eye Diseases

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The EPO published European patent application EP4326764A1, filed by Navigo Proteins GmbH, covering fusion proteins with specificity for type II collagen and VEGF-A for the treatment of eye diseases. The application names inventors Bosse-Doenecke, Eva; Gloser-Braeunig, Manja; Katzschmann, Anja; and Haupts, Ulrich. The patent is classified under C07K 16/22, C07K 14/78, and A61P 27/02, with all EPC contracting states designated.

“FUSION PROTEINS WITH SPECIFITY FOR TYPE II COLLAGEN AND VEGF-A FOR THE TREATMENT OF EYE DISEASES”

EPO , verbatim from source
Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.

What changed

The EPO published European patent application EP4326764A1 filed by Navigo Proteins GmbH, covering fusion proteins with specificity for type II collagen and VEGF-A for use in treating eye diseases. The application names four inventors and is classified under IPC codes C07K 16/22 (immunoglobulins/anti-TGF-beta), C07K 14/78 (collagens/elastin), and A61P 27/02 (ophthalmologicals). All EPC contracting states are designated.

Affected parties include pharmaceutical and biotechnology companies developing fusion protein therapeutics for ophthalmological applications. Patent applicants and technology transfer offices should review the scope of claims in EP4326764A1 for potential freedom-to-operate considerations in the eye disease treatment space.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

FUSION PROTEINS WITH SPECIFITY FOR TYPE II COLLAGEN AND VEGF-A FOR THE TREATMENT OF EYE DISEASES

Publication EP4326764A1 Kind: A1 Apr 15, 2026

Applicants

NAVIGO PROTEINS GMBH

Inventors

BOSSE-DOENECKE, Eva, GLOSER-BRAEUNIG, Manja, KATZSCHMANN, Anja, HAUPTS, Ulrich

IPC Classifications

C07K 16/22 20060101AFI20221028BHEP C07K 14/78 20060101ALI20221028BHEP A61P 27/02 20060101ALI20221028BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Biotechnology research Therapeutic development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!